Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 47579-47581 [2024-12104]
Download as PDF
<![CDATA[
47579
Federal Register / Vol. 89, No. 107 / Monday, June 3, 2024 / Notices
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Assurance of
Compliance with Federal Policy/IRB
Review/IRB Recordkeeping/Informed
Consent/Consent Documentation.
Type of Collection: 3-year extension of
a currently approved collection.
OMB No. 0990–0260
Abstract: The Office of the Assistant
Secretary for Health, Office for Human
Research Protections is requesting a
three-year extension of the Protection of
Human Subjects: Assurance of
Compliance with Federal Policy/IRB
Review/IRB Recordkeeping/Informed
Consent/Consent Documentation, OMB
No. 0990–0260.
Information reported to the Federal
departments and agencies under the
Common Rule with respect to a
satisfactory assurance is used to ensure
that an institution engaged in nonexempt research involving human
subjects conducted or supported by a
Common Rule department or agency has
(1) established adequate administrative
policies and procedures for protecting
the rights and welfare of human subjects
in research, and (2) accepts that
responsibility. Other reporting
requirements are used to: assess
whether the institution is following the
established procedures; ensure that
Federal funds are not expended for
unapproved human subjects research;
and, determine if the approved status of
an awarded grant, contract, or
cooperative agreement should be
reviewed, with the ultimate goal of
maintaining or increasing human
subject protections.
Likely Respondents: institutions and
institutional review boards.
Annualized Burden Hour Tables
TABLE 1—ESTIMATED ANNUAL IRB RECORDKEEPING BURDEN
Common rule
provision
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
.115 [Pre-2018 and 2018 Requirement]—Preparation and
documentation of IRB activities ........................................
6,000
16
96,000
12
1,152,000
Total ..............................................................................
........................
........................
96,000
........................
1,152,000
TABLE 2—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN
Number of
respondents
.109(d) [Pre-2018 and 2018 Requirements]—Written notification of ............................................................................
IRB approval or disapproval of research .............................
.116(a) and (b) (Pre-2018 Requirements)/.116 (b), (c) and
(d) [2018 Requirements]—Elements of informed consent
and broad consent ...........................................................
.116(h)—[2018 Requirements]—Posting clinical trial consent form ..........................................................................
.117(a) [Pre-2018 and 2018 Requirements]—Documentation of informed consent ...................................................
.117(c)(2) [Pre-2018 and 2018 Requirements]—Written
statement about the research when informed consent
documentation is waived ..................................................
Total ..............................................................................
Total
annual
disclosures
150,000
0.5
75,000
6,000
25
150,000
0.5
75,000
425
5
2,125
0.5
1,063
6,000
20
120,000
0.5
60,000
6,000
5
30,000
.5
15,000
........................
........................
452,125
........................
308,563
[FR Doc. 2024–12111 Filed 5–31–24; 8:45 am]
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
18:00 May 31, 2024
Jkt 262001
PO 00000
Total hours
25
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Average
burden per
disclosure
6,000
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
BILLING CODE 4150–36–P
lotter on DSK11XQN23PROD with NOTICES1
Number of
disclosures
per
respondent
Frm 00071
Fmt 4703
Sfmt 4703
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
SUMMARY:
E:\FR\FM\03JNN1.SGM
03JNN1
lotter on DSK11XQN23PROD with NOTICES1
47580
Federal Register / Vol. 89, No. 107 / Monday, June 3, 2024 / Notices
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
2017 (82 FR 7920); and on October 12,
2023 (88 FR 70768).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020, and subsequently
revised in the Federal Register on
October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
VerDate Sep<11>2014
18:00 May 31, 2024
Jkt 262001
order to conduct drug and specimen
validity tests on specimens for Federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid effective
October 10, 2023 (88 FR 70814), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved To Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Dynacare*, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190 (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories Approved
To Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on
urine specimens:
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823 (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
23236, 804–378–9130 (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Desert Tox, LLC, 5425 E Bell Rd, Suite
125, Scottsdale, AZ 85254, 602–457–
5411/623–748–5045
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
Dynacare*, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630 (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Laboratory Corporation of America,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
(Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339 (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088, Testing for Veterans Affairs
(VA) Employees Only
E:\FR\FM\03JNN1.SGM
03JNN1
Federal Register / Vol. 89, No. 107 / Monday, June 3, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Omega Laboratories, Inc.*, 2150
Dunwin Drive, Unit 1 & 2,
Mississauga, ON, Canada L5L 5M8,
289–919–3188
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942 (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085, Testing for
Department of Defense (DoD)
Employees Only
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories continued under
DOT authority. The responsibility for
conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory as meeting
the minimum standards of the current
Mandatory Guidelines published in the
Federal Register. After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program. DOT established this process
in July 1996 (61 FR 37015) to allow
foreign laboratories to participate in the
DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace
Programs.
[FR Doc. 2024–12104 Filed 5–31–24; 8:45 am]
BILLING CODE 4162–20–P
VerDate Sep<11>2014
18:00 May 31, 2024
Jkt 262001
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
[Docket No. DHS–2024–0015]
Department of Homeland Security Data
Privacy and Integrity Advisory
Committee: Request for Applicants for
Appointment
Department of Homeland
Security (DHS).
ACTION: Request for applicants for
appointment to the Department of
Homeland Security Data Privacy and
Integrity Advisory Committee.
AGENCY:
The U.S. Department of
Homeland Security seeks applicants for
appointment to the Data Privacy and
Integrity Advisory Committee.
DATES: Applications for membership
must reach the Department of Homeland
Security Privacy Office via email or fax
within 45 days of the date of this notice.
ADDRESSES: To apply for membership,
please submit the documents described
below to Sandra L. Taylor, Designated
Federal Officer, DHS Data Privacy and
Integrity Advisory Committee, by either
of the following methods:
• Email: PrivacyCommittee@
hq.dhs.gov. Include Docket Number
(DHS–2024–0015) in the subject line of
the message.
• Fax: (202) 343–4010.
FOR FURTHER INFORMATION CONTACT:
Sandra L. Taylor, Designated Federal
Officer, DHS Data Privacy and Integrity
Advisory Committee, Department of
Homeland Security, 2707 Martin Luther
King Jr. Ave. SE, Mail Stop 0655,
Washington, DC 20598–0655, by
telephone (202) 343–1717, by fax (202)
343–4010, or by email
PrivacyCommittee@hq.dhs.gov.
SUPPLEMENTARY INFORMATION: The DHS
Data Privacy and Integrity Advisory
Committee is an advisory committee
established in accordance with the
Federal Advisory Committee Act
(FACA), 5 U.S.C. ch. 10. The Committee
was established by the Secretary of
Homeland Security under 6 U.S.C. 451.
The Committee provides advice at the
request of the Secretary and the Chief
Privacy Officer on programmatic,
policy, operational, security,
administrative, and technological issues
within DHS that relate to personally
identifiable information (PII) and data
integrity, transparency, and other
privacy-related matters. The duties of
the Committee are solely advisory in
nature. In developing its advice and
recommendations, the Committee may,
consistent with FACA, conduct studies,
SUMMARY:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
47581
inquiries, or briefings in consultation
with individuals and groups in the
private sector and/or other
governmental entities. The Committee
holds at least one public meeting per
calendar year.
Committee Membership: The DHS
Privacy Office is seeking applicants for
terms of three years from the date of
appointment. Members are appointed by
and serve at the pleasure of the
Secretary of the U.S. Department of
Homeland Security. Members must be
specially qualified to serve on the
Committee by virtue of their education,
training, and experience in the fields of
data protection, privacy, cybersecurity,
and/or emerging technologies. Members
are expected to actively participate in
Committee and Subcommittee activities
and to provide material input into
Committee research and
recommendations. Pursuant to the
FACA, the Committee’s Charter requires
that Committee membership be
balanced to include:
1. Individuals currently working in
higher education, state or local
government, or not-for-profit
organizations;
2. Individuals currently working in
for-profit organizations including at
least one who shall be familiar with the
data privacy-related issues addressed by
small- to medium-sized enterprises;
3. Individuals currently working in
for-profit organizations, including at
least one who shall be familiar with data
privacy-related issues addressed by
large-sized and/or multinational
enterprises; and
4. Other individuals, as determined
appropriate by the Secretary.
Committee members serve as Special
Government Employees (SGE) as
defined in section 202(a) of title 18
U.S.C. As such, they are subject to
Federal conflict of interest laws and
government-wide standards of conduct
regulations. Members must annually file
a New Entrant Confidential Financial
Disclosure Report (OGE Form 450) for
review and approval by Department
ethics officials. DHS may not release
these reports or the information in them
to the public except under an order
issued by a Federal court or as
otherwise permitted under the Privacy
Act (5 U.S.C. 552a) or Freedom of
Information Act (FOIA) (5 U.S.C. 552).
Committee members are also required to
obtain and retain at least a secret-level
security clearance as a condition of their
appointment. Members are not
compensated for their service on the
Committee; however, while attending
meetings or otherwise engaged in
Committee business, members may
receive travel expenses and per diem in
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 89, Number 107 (Monday, June 3, 2024)]
[Notices]
[Pages 47579-47581]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-12104]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine and Oral Fluid Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and the laboratories currently
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
FOR FURTHER INFORMATION CONTACT: Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240-276-
[[Page 47580]]
2600 (voice); [email protected] (email).
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) publishes a notice listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities (IITFs) in the Federal Register
during the first week of each month, in accordance with section 9.19 of
the Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any laboratory or IITF certification is
suspended or revoked, the laboratory or IITF will be omitted from
subsequent lists until such time as it is restored to full
certification under the Mandatory Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace/drug-testing-resources/certified-lab-list.
HHS separately notifies Federal agencies of the laboratories and
IITFs currently certified to meet the standards of the Mandatory
Guidelines using Urine and of the laboratories currently certified to
meet the standards of the Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using Urine were first published in the
Federal Register on April 11, 1988 (53 FR 11970), and subsequently
revised in the Federal Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23, 2017 (82 FR 7920); and on October
12, 2023 (88 FR 70768).
The Mandatory Guidelines using Oral Fluid were first published in
the Federal Register on October 25, 2019 (84 FR 57554) with an
effective date of January 1, 2020, and subsequently revised in the
Federal Register on October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71 and
allowed urine drug testing only. The Mandatory Guidelines using Urine
have since been revised, and new Mandatory Guidelines allowing for oral
fluid drug testing have been published. The Mandatory Guidelines
require strict standards that laboratories and IITFs must meet in order
to conduct drug and specimen validity tests on specimens for Federal
agencies. HHS does not allow IITFs to conduct oral fluid testing.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-
certified laboratory or IITF must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility
has met minimum standards. HHS does not allow IITFs to conduct oral
fluid testing.
HHS-Certified Laboratories Approved To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory Guidelines using Oral Fluid
effective October 10, 2023 (88 FR 70814), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on oral fluid specimens:
At this time, there are no laboratories certified to conduct drug
and specimen validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial Testing Facilities Approved To
Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
Dynacare*, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190 (Formerly: Gamma-Dynacare Medical Laboratories)
HHS-Certified Laboratories Approved To Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on urine specimens:
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917
Desert Tox, LLC, 5425 E Bell Rd, Suite 125, Scottsdale, AZ 85254, 602-
457-5411/623-748-5045
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
Dynacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630 (Formerly: Gamma-Dynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Laboratory Corporation of America, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295 (Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088,
Testing for Veterans Affairs (VA) Employees Only
[[Page 47581]]
Omega Laboratories, Inc.*, 2150 Dunwin Drive, Unit 1 & 2, Mississauga,
ON, Canada L5L 5M8, 289-919-3188
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085, Testing for
Department of Defense (DoD) Employees Only
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories continued under DOT authority.
The responsibility for conducting quarterly performance testing plus
periodic on-site inspections of those LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS' NLCP contractor continuing
to have an active role in the performance testing and laboratory
inspection processes. Other Canadian laboratories wishing to be
considered for the NLCP may apply directly to the NLCP contractor just
as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory as meeting the minimum
standards of the current Mandatory Guidelines published in the Federal
Register. After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program. DOT
established this process in July 1996 (61 FR 37015) to allow foreign
laboratories to participate in the DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2024-12104 Filed 5-31-24; 8:45 am]
BILLING CODE 4162-20-P
